



BD Neopak™

Glass Pre-fillable Syringe

Change to the reliability
of BD Neopak™ platform to accompany
your brand strategy



Legacy drugs under Life Cycle Management

Anticipating and managing change through life cycle management strategy is a key success factor for all major biopharmaceutical companies. Pharma companies considering life cycle management solution options need to reconcile:

- Brand strategy and **differentiation**
- Optimizing manufacturing **process** and **cost**
- Risk mitigation associated to **combination product interactions**

BD Neopak™ Glass Pre-fillable Syringe platform is built on years of BD's unmatched experience partnering with leading biopharmaceutical companies to support drug development and launch. BD Neopak™ was conceived with a solution finding mindset, allowing to tangibly meet your current and future needs for biotech drugs.

- > BD Neopak™ platform options and product features to support your life cycle management brand strategy.



BD Neopak™ platform options and product features to support your life cycle management brand strategy


- BD Neopak™ provides a wealth of portfolio options and compatibility with BD injection solutions


Barrel formats
1 mL, 2.25 mL

Needle gauges
27G Special Thin Wall,
29G Thin Wall, 25G Thin Wall

Needle shield rubber formulations
BD260, FM30, 4800

Flange designs
Small Round Flange
Small Extra-round Flange






68
BD Neopak™ references
26 already available
42 are being developed


+

BD Safety Systems

BD UltraSafe Passive™
Needle Guard




BD UltraSafe Plus™
Passive Needle Guard




Self-Administered Injection Systems*


BD Physioject™
Disposable Autoinjector



BD Intevia™
Disposable Autoinjector



BD Libertas™
Wearable Injector



*BD Intevia™, BD Libertas™, UltraSafe Plus™ 2.25, are products in development and are subject to a variety of risks and uncertainties

- BD Neopak™ offers unique features¹ allowing to contain costs and minimize risks

- ✓ **Dead volume** under control (<5µL)
- ✓ **Minimized glue extractibles**
- ✓ **Minimized glass particles**
- ✓ **Certificate of analysis** supplied with **delegation of control**
- ✓ **Autoinjector compatibility** ensured through dimensional precision
- ✓ **Autoinjector performance** through gliding force control (<2.5N)

BD Neopak™ offer can potentially reduce your total cost of ownership by delivering savings against existing syringe types.

Customer case study showed:

BD Neopak™ displayed

90%

reject rate reduction

compared to standard pre-fillable syringe offer²

- Shifting to BD Neopak™ BD Regulatory Affairs service supports smooth transition to new BD syringe

General assessment of customer's regulatory impact of a switch*

e.g. BD Hypak™ for Biotech to BD Neopak™ Pre-fillable Syringe

- Explains the change & regulatory impact
- Clarifies how to handle change and what supportive documentation to generate



BD Medical
Pharmaceutical Systems
United States
1 Becton Drive
Franklin Lakes, NJ 07417
+1 800 225 3310
Europe
11 rue Aristide-Bergès
38800 Le Pont-de-Claix
France
Phone: +33 4 76 68 36 36
Fax: +33 4 76 68 35 05
Becton Dickinson France S.A.S
Share capital: 64 719 915 €
RCS Grenoble B 056 501 711

bd.com

BD, the BD Logo, BD Hypak, BD Intevia, BD Libertas, BD Neopak, BD Physioject, BD UltraSafe Passive and BD UltraSafe Plus, are property of Becton, Dickinson and Company, or its affiliates. © 2020 BD. All rights reserved

